screen_shot_2015-02-20_at_14

Chair appointed for new MHRA devices committee

pharmafile | February 20, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MHRA, Peter Nightingale, deac 

Dr Peter Nightingale has been appointed as chairman of the Medicines and Healthcare products Regulatory Agency’s (MHRA) newly-formed Devices Expert Advisory Committee (DEAC).

DEAC has been formed following a review on MHRA access to clinical advice and engagement with the clinical community, and replaces its Committee on the Safety of Devices. 

Responsible for providing advice to the agency in support of its role to ensure that medical devices are acceptably safe, it will also support the agency in developing and maintaining collaborative relationships with clinical professional bodies. 

Advertisement

Nightingale is a consultant in anaesthesia and intensive care medicine and was president of the Royal College of Anaesthetists until September 2012. He was formerly president of the Intensive Care Society and vice chair of the Academy of Medical Royal Colleges.

MHRA Devices director John Wilkinson says: “I am delighted that Dr Nightingale has accepted this appointment. His expertise and experience will be invaluable in helping the agency as it responds to the demands of the future.”

Nightingale adds: “I am delighted to be taking on this role. The new committee will play a vital role in providing expert advice for MHRA on a huge range of medical issues and will help to ensure safe use and management of medical devices.”

Related Content

IMed Consultancy releases white paper on Digital Mental Health Technologies

IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has …

Dual immunotherapy for bowel cancer now available under NHS

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …

MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients

The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in …

The Gateway to Local Adoption Series

Latest content